Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.93
Nov 17 • 3:58 PM ET Dollar change-0.07 Percentage change(-3.50%)
Aftermarket Close
2.01
Aftermarket • 7:30 PM ET Dollar change+0.08 Percentage change(3.89%)
Index
-
Market Cap
3.51M
Enterprise Value
2.46M
Income
-15.41M
Sales
5.53M
Book/sh
3.36
Cash/sh
1.40
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
57
IPO
Sep 01, 2022
P/E
-
Forward P/E
-
PEG
-
P/S
0.63
P/B
0.58
P/C
1.38
P/FCF
-
EV/EBITDA
-
EV/Sales
0.44
Quick Ratio
1.47
Current Ratio
1.51
Debt/Eq
0.38
LT Debt/Eq
0.28
Option/Short
No / Yes
EPS (ttm)
-38.13
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
45.79% 21.77%
Sales past 3/5Y
986.60% -
EPS Y/Y TTM
87.82%
Sales Y/Y TTM
-18.47%
EPS Q/Q
91.71%
Sales Q/Q
-25.99%
Insider Own
0.82%
Insider Trans
0.00%
Inst Own
9.32%
Inst Trans
3.88%
ROA
-161.37%
ROE
-240.48%
ROIC
-306.97%
Gross Margin
20.41%
Oper. Margin
-246.14%
Profit Margin
-278.93%
SMA20
-29.02%
SMA50
-61.05%
SMA200
-89.41%
Trades
Shs Outstand
1.82M
Shs Float
1.81M
52W High
80.70 -97.61%
52W Low
1.96 -1.53%
Volatility
9.74% 11.02%
ATR (14)
0.47
RSI (14)
29.81
Beta
-0.88
Rel Volume
0.02
Avg Volume
3.67M
Volume
68,087
Perf Week
-19.25%
Perf Month
-45.01%
Perf Quarter
-68.54%
Perf Half Y
-92.43%
Perf YTD
-89.10%
Perf Year
-91.86%
Perf 3Y
-99.69%
Perf 5Y
-
Perf 10Y
-
Prev Close
2.00
Price
1.93
Change %
-3.50%
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
Founder & Executive Chairman of the BoardMr. Steven Girgenti
FounderMs. Maria Zannes J.D.
M.B.A.Mr. James Michael Edwards CPA
Chief Operating OfficerMr. Xavier T. Reveles M.S.
Chief Science OfficerDr. William Bauta Ph.D.